ENHANCED ANTIGEN IMMUNOGENICITY INDUCED
BY BISPECIFIC ANTIBODIES

By DENIS P. SNIDER,* ANDREAS KAUBISCH, AND DAVID M. SEGAL

From the Experimental Immunology Branch, National Cancer Institute,
National Institutes of Health, Bethesda, Maryland 20892; and the *Department of Pathology,
McMaster University, Hamilton, Ontario L8N-3Z5, Canada

Th cells recognize and respond to processed antigen bound to class II MHC molecules on the surfaces of APC (1, 2). In vitro, the targeting of antigen to APC surfaces by heterocrosslinked bispecific antibodies (HBAs) greatly increases the efficiency with which APC endocytose, process, and present antigen to T cells (3–5). Since antibody responses against most protein antigens require T cell help in vivo, we have asked here if HBAs could also enhance the ability of an antigen, in this case hen egg lysozyme (HEL), to induce an antibody response in mice. HBAs were prepared by chemically crosslinking an antibody with specificity for HEL to various other antibodies, each specific for a particular APC cell surface component. Normally, the generation of immune responses after immunization with vaccines and other antigens requires relatively large amounts of antigen, multiple injections, and, in experimental animals, adjuvants (6, 7). By contrast, we show that HBAs, when administered once with nanogram amounts of antigen, in the absence of adjuvant, induce high titers of antibody in mice, and prime mice for a secondary IgG antibody response when rechallenged with soluble antigen.

Materials and Methods

Immunizations and Measurements of Antibody Production. Mice of various strains were given primary injections containing various amounts of HEL (Sigma Chemical Co., St. Louis, MO) or HEL mixed with 5–10 μg of HBA in PBS, in two portions of 50 μl in each hind footpad. Controls received PBS alone. Mice were bled 21 d after the primary injection, and the next day given a secondary challenge of 5–10 μg of HEL (5 μg per hind footpad). 11 d later, the mice were bled again, sera were isolated, and anti-HEL IgG antibody was measured using a solid-phase ELISA. In the ELISA, HEL was bound to plastic microtiter wells and incubated sequentially with dilutions of each test serum, biotin anti-mouse IgG (Southern Biotechnology Assoc., Birmingham, AL), avidin-alkaline phosphatase (Sigma Chemical Co.), and finally, substrate (Sigma Chemical Co.). The amount of antibody in each serum was interpolated from the dose-response curve of a standard pool of hyperimmune sera, giving an arbitrary value of antibody U/ml.

Antibodies. All HBAs used in this paper were prepared by chemically crosslinking mAbs with succinimidyl-3-(2 pyridyldithiol)propionate as described (8). HBAs were separated from uncrosslinked monomeric antibodies by gel filtration and are designated “antibody 1 × anti-

Address correspondence to David M. Segal, Experimental Immunology Branch, National Cancer Institute, Building 10, Room 4B17, National Institutes of Health, Bethesda, MD 20892.

1 Abbreviations used in this paper. HBA, heterocrosslinked bispecific antibodies; HEL, hen egg lysozyme.
body 2. For example, anti-\(\text{I-A}^k\times\text{anti-HEL}\) refers to a gel filtration fraction of 300 kD or greater, obtained when anti-\(\text{I-A}^k\) was crosslinked to anti-HEL. Antibodies used in this paper are anti-HEL, HyHEL-8 (9); anti-\(\text{I-A}^k\), 10-2.16 (10); anti-\(\text{I-A}^d\), MKD6 (11); anti-\(\text{K}^d\text{D}^d\), 34.1.2 (12); anti-\(\text{K}^d\), 36.7.5 (12); anti-Fc,RII, 2.4G2 (13); anti-IgD\(^{\gamma}\), AM028.1 (14); and anti-IgD\(^{\mu}\), AF3-33.3 (14). Fab fragments were produced by papain digestion and were purified by gel filtration followed by ion exchange chromatography (15).

Results and Discussion

Female A/J mice were given subcutaneous injections of graded amounts of HEL or HEL mixed with HBAs, on day 0. 21 d later, the mice were bled to determine serum anti-HEL IgG antibody levels. On day 22, the mice were given booster injections of 5 \(\mu\)g of HEL per hind foot pad, to induce secondary IgG antibody responses. Sera were collected 11 d later and IgG antibody was measured. Fig. 1 shows that >10 \(\mu\)g of HEL per mouse was required in a primary injection to produce either a primary or a secondary IgG antibody response, if the HEL was given alone. However, in the presence of 10 \(\mu\)g of HBA (anti-\(\text{I-A}^k\times\text{anti-HEL}\)), 100 ng of HEL induced a substantial primary IgG antibody response, and as little as 10 ng of HEL induced a strong secondary response. In other experiments (e.g., Fig. 2), <1 ng of HEL in the presence of HBA gave a significant secondary response. Mice receiving PBS as a primary injection, and then given a secondary challenge of HEL (Fig. 1), or given the HBA alone as a primary injection and then a secondary challenge of HEL (Fig. 2), produced little or no IgG antibody. We compared immunization using HBAs with that of HEL emulsified in IFA (Fig. 2). The two types of immunization produced similar amounts of IgG antibody in the secondary response, especially at low HEL doses. Thus, the HBA specific for HEL and class II MHC structures increased the efficiency of immunization by 300-fold in the primary response, and by a factor of \(10^3\) to \(10^4\) after a secondary boost. The HBA increased the efficiency of priming for secondary IgG antibody responses at least as well as IFA.

We constructed several other HBAs that could bind to different surface molecules

![Figure 1. HBA enhancement of antibody responses in vivo.](image-url)
on various APC, and used them to immunize mice (Table I). HBAs specific for class I or class II MHC molecules, or FcγRII, all enhanced the ability of HEL to induce antibody responses in different strains of mice. However, two HBAs with specificity for two allotypes of IgD when tested in several strains of mice induced little or no anti-HEL antibody (Table I, Exp. 2). In other experiments (not shown), we were unable to generate a significant anti-HEL response by varying the dosages of the IgD-specific HBAs and HEL from 20 to 0.1 μg. These same IgD-specific HBAs enhance the efficiency of presentation of HEL to Th hybridomas by B cells in vitro.

Table I

| Exp. | Mouse strain | Haplotype | HBA in primary injection | IgG anti-HEL responses |
|------|--------------|-----------|--------------------------|------------------------|
|      |              | KID       |                          | Primary U/ml x 10^{-3} | Secondary U/ml x 10^{-3} |
| 1    | CAF1         | ddd x kkd | -                        | 7(0)*                  | 7(0)                     |
|      |              |           | Anti-I-A^b × anti-HEL    | 8(1)                   | 166(60)                  |
|      |              |           | Anti-K^+D^d × anti-HEL   | 7(0)                   | 33(11)                   |
|      |              |           | Anti-FcγRII × anti-HEL   | 8(1)                   | 40(15)                   |
|      | A/J          | kkd       | -                        | ND                     | 9(4)                     |
|      |              |           | Anti-I-A^b × anti-HEL    | 63(15)                 | 933(200)                 |
|      |              |           | Anti-K^b × anti-HEL      | 14(12)                 | 302(115)                 |
|      |              |           | Anti-FcγRII × anti-HEL   | 13(11)                 | 269(70)                  |
| 2    | CAF1         | ddd x kkd | -                        | 2(0)                   | 3(2)                     |
|      |              |           | Anti-I-A^b × anti-HEL    | 19(6)                  | 118(14)                  |
|      |              |           | Anti-IgD^a × anti-HEL    | 2(0)                   | 9(4)                     |
|      | B10.BR       | kkk       | -                        | 2(0)                   | 3(0)                     |
|      |              |           | Anti-I-A^b × anti-HEL    | 19(10)                 | 39(5)                    |
|      |              |           | Anti-IgD^b × anti-HEL    | 3(1)                   | 12(2)                    |

Groups of 4–5 female mice of different strains were given primary injections of 2 μg of HEL with or without 10 μg of HBA, having the indicated specificities. After 21 d, each mouse was given a second injection of 10 μg of HEL in PBS. Sera were collected 11–13 d later, and anti-HEL IgG antibody was measured and is shown as U/ml. The limits of detection were 7,000 U/ml for Exp. 1 and 2,000 U/ml for Exp. 2.

* Figures in parentheses are SEM.
The inability of anti-sIgD-containing HBAs to enhance immunogenicity suggests that either these HBA antigen complexes, when given subcutaneously, do not bind to B cells in vivo (e.g., they might be cleared rapidly or circulating IgD might block their binding to B cells), or that B cells are not able to stimulate unprimed T cells in vivo. B cells appear to serve as in vivo APC to stimulate T cell proliferation in other systems (16–20).

Several important controls for the effect of HBAs are shown in Table II. First, HBAs enhanced antibody production only if the appropriate antibodies were in fact crosslinked; monomeric mixtures of antibodies did not work (Table II, Exp. 1). Second, antibody was induced only if the strain of mouse immunized expressed the structures to which the HBA could bind (Table II, Exp. 2). Thus, HBAs with I-A\textsuperscript{d} or K\textsuperscript{d}D\textsuperscript{d} specificities did not produce responses in H-2\textsuperscript{k} (C3H) mice, but did produce responses in H-2\textsuperscript{k} × H-2\textsuperscript{d} (CAF1) mice. The same I-A\textsuperscript{d}-specific HBA did not induce antibody in A/J mice, but the K\textsuperscript{d}D\textsuperscript{d}-specific HBA did, since this strain expresses D\textsuperscript{d} but not I-A\textsuperscript{d}. Both the C3H and the A/J mice responded when immunized with the HEL- and FcyRII-specific HBA.

Because antigen targeted to FcyRII gave enhanced antibody responses to HEL in several strains, it was important to show that the HBAs were not simply forming immune complexes with HEL and binding via their Fc portions to FcyR on APC. Therefore, we constructed an HBA from Fab fragments of anti-HEL and anti-I-A\textsuperscript{k} mAbs, and compared its ability to induce anti-HEL antibody with that of its intact Ig counterpart (Table II, Exp. 3). The results show that the Fab-HBA performed as well as the intact Ig-HBA over a range of dosages, indicating that the Fc regions of the HBA were not required for enhanced antibody production. This conclusion is also supported by the observation that anti-H-2\textsuperscript{d}-specific HBAs did not promote antibody production in H-2\textsuperscript{k} (i.e., C3H) mice (Table II, Exp. 2).

It is likely that HBAs increase anti-HEL production in mice by targeting HEL to surface structures on APC in vivo. Such targeting would cause the antigen to be processed and presented to T cells with much higher efficiency than antigen given alone, as documented in vitro (3–5). Presumably, such APC could then generate large numbers of antigen-specific Th cells, which in turn would stimulate antigen-specific B cells. The known T cell dependence of anti-HEL responses in mice (21, 22) supports this view.

Our use of HBAs to enhance immunization follows on previous results (18, 23–25), showing that antigens that were chemically crosslinked directly to antibodies specific for class II MHC or IgM molecules were more potent immunogens than antigens given alone. HBAs provide several important advantages over chemically linked antigen-antibody conjugates. First, HBAs could be used to enhance responses against small amounts of impure antigens, for example, tumor antigens, whereas direct linkage of antigen to antibody requires relatively large amounts of highly purified antigen. HBAs do not require biochemical modification of antigen, which could alter its immunogenicity. In addition, bispecific antibodies in the form of hybrid-hybridomas (26, 27) or hetero-F(ab')\textsubscript{2} (28) can be prepared as single homogeneous species, whereas antibody-antigen chemical complexes are heterogeneous, and vary between preparations. Therefore, homogeneous bispecific antibodies would be much more suitable for large scale production than the antigen-antibody chemical complexes. Finally, we have found that the microgram amounts of HBAs used in this study are
Table II
Form, Specificity, and Dose of HBA Required for Enhancement of Humoral Responses

| Exp | Mouse strain | Antibody (form) | Ab dose | HEL dose | Secondary response: IgG anti-HEL |
|-----|--------------|----------------|---------|----------|---------------------------------|
|     |              |                | µg      | µg       | U/ml × 10⁻³                      |
| 1   | A/J          | Anti-I-A³ × anti-HEL (HBA) | 5       | 1        | 250(59)*                        |
|     |              | Anti-I-A³ + anti-HEL (mix)  | 5       | 1        | 9(3)                            |
|     |              | Anti-Fc,RII × anti-HEL (HBA) | 5       | 1        | 120(21)                         |
|     |              | Anti-Fc,RII × anti-HEL (mix) | 5       | 1        | 11(2)                           |
|     |              | Anti-HEL (mAb)     | 2.5     | 1        | 10(3)                           |
|     |              | None              | 0       | 1        | 11(6)                           |
|     |              | None              | 0       | 0        | 7(0)                            |
| 2   | CAFI         | Anti-I-A³ × anti-HEL (HBA) | 10      | 3        | 240(65)                         |
|     |              | Anti-K²D⁴ × anti-HEL (HBA) | 10      | 3        | 174(70)                         |
|     |              | None              | 0       | 3        | 3(0)                            |
|     | C3H/HeJ      | Anti-I-A³ × anti-HEL (HBA) | 10      | 3        | 8(4)                            |
|     |              | Anti-K²D⁴ × anti-HEL (HBA) | 10      | 3        | 5(3)                            |
|     |              | Anti-Fc,RII × anti-HEL (HBA) | 10      | 3        | 245(95)                         |
|     |              | None              | 0       | 3        | 11(5)                           |
|     | A/J          | Anti-I-A³ × anti-HEL (HBA) | 10      | 3        | 18(9)                           |
|     |              | Anti-K²D⁴ × anti-HEL (HBA) | 10      | 3        | 112(69)                         |
|     |              | Anti-Fc,RII × anti-HEL (HBA) | 10      | 3        | 302(122)                        |
|     |              | None              | -       | 3        | 13(2)                           |
| 3   | A/J          | Anti-I-A³ × anti-HEL (HBA) | 1       | 2        | 417(129)                        |
|     |              | Anti-I-A³ × anti-HEL (HBA) | 3       | 2        | 525(185)                        |
|     |              | Anti-I-A³ × anti-HEL (HBA) | 10      | 2        | 372(55)                         |
|     |              | Anti-I-A³ × anti-HEL (Fab-HBA) | 1       | 2        | 1,122(440)                      |
|     |              | Anti-I-A³ × anti-HEL (Fab-HBA) | 3       | 2        | 603(209)                        |
|     |              | Anti-I-A³ × anti-HEL (Fab-HBA) | 10      | 2        | 587(124)                        |
|     |              | None              | 0       | 2        | 1(0)                            |

Groups of female mice (4–5 per group) were injected with the indicated doses of HEL or antibody. In Exp. 1, the effect of HBAs on the anti-HEL antibody response was compared with that of the uncross-linked fraction (mix) obtained during purification of HBAs, and to that of the anti-HEL mAb alone. In Exp. 2, the specificity of targeting was tested in mouse strains that express structures to which particular HBAs bind or do not bind. C3H/HeJ and A/J mice were also immunized with HEL plus an anti-Fc,RII-specific HBA as a control for their ability to respond to targeted HEL. The isotypes and allotypes of antibodies used in this experiment were as follows: anti-I-A³ (MKD6), mouse IgG2a, IgH1-b or -e (strain of origin, B6 × A/J); anti-K²D⁴ (34.1.2), mouse IgG2a, IgH1-j (strain of origin, C3H); anti-HEL (HyHEL-8), mouse IgG1, IgH4-a (strain of origin, BALB/C); anti-Fc,RII (2.4G2), rat IgG2b. There is no obvious relationship between possible alloreactivities against HBAs and their ability to enhance anti-HEL production. In Exp. 3, anti-I-A³ × anti-HEL HBAs prepared from intact antibodies or from Fab fragments were compared for their ability to induce anti-HEL antibody. In all experiments, mice were bled 11–14 d after a secondary injection of 10 µg of HEL in PBS. Data are mean U/ml of serum IgG antibody. The limits of detection were 7,000 U/ml (Exp. 1), 3,000 U/ml (Exp. 2), and 1,000 U/ml (Exp. 3).

* Figures in parentheses are SEM.

Remarkably potent enhancers of immunogenicity, leading to priming with nanogram amounts of antigen. Such enhancements of immunogenicity are far greater than those reported in studies using antigen-antibody chemical complexes. Our observations that relatively small amounts of HBAs can enhance antibody responses at least as well as IFA suggests that HBAs may be useful in immunizing man and domestic animals against bacterial, viral, parasitic, and, perhaps, tumor antigens. Such im-
munization would be efficient and would avoid the use of adjuvants that have unwanted inflammatory effects (29), and cannot, therefore, be used in humans.

Summary

The binding of protein antigens to APC with heterocrosslinked bispecific antibodies (HBAs) enhances their processing and presentation to Th cells in vitro. Here we have asked whether HBAs could also increase immune responses in vivo. We immunized mice with hen egg lysozyme (HEL) in the presence or absence of HBA, and followed antibody production after the primary challenge and after a secondary boost. We found that HBAs that bind antigen to MHC class I or II molecules, to FcγR, but not to surface IgD, enhance the immunogenicity of HEL. HBAs that bound HEL to MHC class II molecules, for example, decreased the amount of antigen required to elicit a primary anti-HEL antibody response in mice by 300-fold, and the amount required to prime for a secondary response by $10^2$- to $10^4$-fold. In fact, HBAs were as effective as IFA in generating antibody responses. Since adjuvants cannot be used in humans, HBAs could prove useful for immunizing people, especially in cases where, due to scarcity or toxicity, minute doses of antigen must be used.

Received for publication 20 December 1989 and in revised form 26 February 1990.

References

1. Chesnut, R. W., and H. M. Grey. 1985. Antigen presenting cells and mechanisms of antigen presentation. CRC Crit. Rev. Immunol. 5:236.
2. Allen, P. M., B. P. Babbitt, and E. R. Unanue. 1987. T-cell recognition. Immunol. Rev. 98:171.
3. Snider, D. P., and D. M. Segal. 1987. Targeted antigen presentation using crosslinked antibody heteroaggregates. J. Immunol. 139:1609.
4. Snider, D. P., and D. M. Segal. 1989. Efficiency of antigen presentation following antigen targeting to surface IgD, IgM, MHC, FcγRII, and B220 molecules on murine splenic B cells. J. Immunol. 143:59.
5. Ozaki, S., and J. A. Berzofsky. 1987. Antibody conjugates mimic specific B cell presentation of antigen: relationship between T and B cell specificity. J. Immunol. 138:4133.
6. Warren, H. S., F. R. Vogel, and L. A. Chedid. 1986. Current status of immunological adjuvants. Annu. Rev. Immunol. 4:369.
7. Edelman, R. 1980. Vaccine adjuvants. Rev. Infect. Dis. 2:370.
8. Titus, J. A., M. A. Garrido, T. T. Hecht, D. F. Winkler, J. R. Wunderlich, and D. M. Segal. 1987. Human T cells targeted with anti-T3 crosslinked to anti-tumor antibody prevent tumor growth in nude mice. J. Immunol. 138:4018.
9. Smith-Gill, S. J., A. C. Wilson, M. Potter, E. M. Pager, R. J. Feldmann, and C. R. Mainhart. 1982. Mapping the antigenic epitope for a monoclonal antibody against lysozyme. J. Immunol. 128:314.
10. Oi, V. T., J. W. Jones, L. A. Goding, and L. A. Herzenberg. 1978. Properties of monoclonal antibodies to mouse Ig allotypes, H-2 and Ia antigens. Curr. Top. Microbiol. Immunol. 81:115.
11. Kappler, J. W., B. Skidmore, J. White, and P. Marrack. 1981. Antigen-inducible, H-2-restricted, interleukin 2-producing T cell hybridomas. Lack of independent antigen and H-2 recognition. J. Exp. Med. 153:1198.
12. Sachs, D. H., N. Mayer, and K. Ozato. 1981. Hybridoma antibodies directed toward
murine H-2 and Ia antigens. In Monoclonal Antibodies and T-cell Hybridomas. J. Hammerling, U. Hammerling, and J. F. Kearney, editors. Elsevier Science Publishing Co., Inc., New York. 95–121.

13. Unkeless, J. C. 1979. Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fe receptors. J. Exp. Med. 150:580.

14. Goroff, D. K., A. Still, J. J. Mond, and F. D. Finkelman. 1986. In vitro and in vivo B lymphocyte-activating properties of monoclonal anti-δ antibodies. 1. Determinants of B lymphocyte-activating properties. J. Immunol. 136:2382.

15. Perez, P., R. W. Hoffman, J. A. Titus, and D. M. Segal. 1986. Specific targeting of human peripheral blood T cells by heteroaggregates containing anti-T3 crosslinked to anti-target cell antibodies. J. Exp. Med. 163:166.

16. Janeway, C. A., Jr., J. Ron, and M. E. Katz. 1987. The B cell is the initiating antigen-presenting cell in peripheral lymph nodes. J. Immunol. 138:1051.

17. Ron, Y., and J. Sprent. 1987. T cell priming in vivo: a major role for B cells in presenting antigen to T cells in lymph nodes. J. Immunol. 138:2848.

18. Kawamura, H., and J. A. Berzofsky. 1986. Enhancement of antigenic potency in vitro and immunogenicity in vivo by coupling the antigen to anti-immunoglobulin. J. Immunol. 136:58.

19. Kurt Jones, E. A., D. Liano, K. A. HayGlass, B. Benacerraf, M.-S. Sy, and A. K. Abbas. 1988. The role of antigen-presenting B cells in T cell priming in vivo studies of B cell-deficient mice. J. Immunol. 130:3773.

20. Ashwell, J. D. 1988. Are B lymphocytes the principal antigen-presenting cells in vivo? J. Immunol. 140:3697.

21. Gammon, G., N. Shastri, J. Cogswell, S. Wilbur, S. Sadegh-Nasseri, U. Krzych, A. Miller, and E. E. Sercarz. 1987. The choice of T-cell epitopes utilized on a protein antigen depends on multiple factors distant from, as well as at the determinant site. Immunol. Rev. 98:53.

22. Hill, S. W., and E. E. Sercarz. 1975. Fine specificity of the H-2 linked immune response gene for the gallinaceous lysozymes. Eur. J. Immunol. 5:317.

23. Carayanniotis, G., and B. H. Barber. 1987. Adjuvant-free IgG responses induced with antigen coupled to antibodies against class II MHC. Nature (Lond.). 327:59.

24. Carayanniotis, G., E. Vizi, J. M. Parker, R. S. Hodges, and B. H. Barber. 1988. Delivery of synthetic peptides by anti-class II MHC monoclonal antibodies induces specific adjuvant-free IgG responses in vivo. Mol. Immunol. 25:907.

25. Pierce, S. K., and L. A. Casten. 1988. Soluble globular protein antigens covalently coupled to antibodies specific for B cell surface structures are effective antigens both in vitro and in vivo. In Antigen Presenting Cells: Diversity, Differentiation, and Regulation. L. B. Schook and J. G. Tew, editors. Alan R. Liss, Inc., New York. 259–268.

26. Staerz, U. D., and M. J. Bevan. 1986. Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc. Natl. Acad. Sci. USA. 83:1453.

27. Lanzavecchia, A., and D. Scheidegger. 1987. The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur. J. Immunol. 17:105.

28. Glennie, M. J., H. M. McBride, A. T. Worth, and G. T. Stevenson. 1987. Preparation and performance of bispecific F(ab')2 antibody containing thioether-linked Fab'γ fragments. J. Immunol. 139:2367.

29. Dietzschold, B., H. H. Wang, C. E. Rupprecht, E. Celis, M. Tollis, H. Ertl, E. Heber-Katz, and H. Koprowski. 1987. Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein. Proc. Natl. Acad. Sci. USA. 84:9165.